Drug Trial Radar · NCT04930809
Single and Multiple Dose Study of VER-01 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Nov 25, 2021
Primary completion
Jul 4, 2022
Study completion Jul 11, 2022
Sponsor
- Lead sponsor
- Vertanical GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers
Conditions
- Healthy
Interventions
VER-01Drug
standardised cannabis extract (containing 21 mg THC per gram drug product)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-tTime frame: Group A-D: Day 1; Group E-G: Day 1 and 4
- Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-∞Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4
- Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - C maxTime frame: Group A-D: Day 1; Group E-G: Day 1 and 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Medicine in Vienna - Department of Clinical Pharmacology
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.